Our Company
Fresenius Medical Care Worldwide
Products
Press ReleasesTherapeutic Apheresis
Due to the increasing dosages in the therapies that rely on the administration of pharmaceuticals and because it is becoming more and more frequent to have adverse side effects, Fresenius Medical Care provides an alternative, a variety of therapeutic apheresis (treatment through the extracorporeal circuit) that aim to selectively adsorb, from the patients' blood, specific components associated to certain diseases.
For more information send an email to:
comercial-marketing@fmc-ag.com
| Equipment | Clinical/Therapeutic Indications |
| DALI | Therapeutic Indications for hypercholesterolaemia (homozygous and heterozygous) |
| Immunosorba | An indicated treatment for autoimmune diseases, namely Guillian-Barré Syndrome, Haemophilia with inhibitors to factor VIII and IX, Dilated Cardiomyopathy, Myasthenia Gravis and Acute Humoral Rejection (AHR). |
DALI
The DALI therapy consists of an LDL apheresis tecnique through the direct adsorption of lipoproteins (without plasma separation).
This therapy is indicated for hypercholesterolaemia, and it is clinically proven that it results in the patient's arteriosclerosis stabilisisation regression, in the long term.
The principle of direct adsorption significantly reduces the extracorporeal blood volume as well as the duration of the treatment, with clear benefits for the patients.
The DALI therapy ensures a removal rate of LDL Cholesterol of up to 76% and of Lipoprotein Lp(a) up to 70%, resulting in the increase of the LDL/HDL ratio at the end of each treatment.
As a general rule, treatments are carried out every two weeks and last for an average of 2 hours.
Download Technical Form(104KB)
Immunosorba
The Immunosorba therapy consists of an immunoadsorption therapy procedure where specific antibodies and circulating immune complexes, associated with autoimmune diseases, are removed from the patient's plasma.
The adsorption effect derives from the binding affinity of Protein A to the IgG (subclass 1, 2 and 4), IgA and IgM antibodies.
The treatment is carried out in an extracorporeal circuit, through the continuous plasma separation done by a Cell Separator (AS.TEC 204, COM.TEC). Using the monitor Citem 10, the plasma obtained is them processed through one of the two Immunosorba® columns where the adsorption process takes place.
The duration of the treatments usually ranges between 3 to 5 hours and depends also of the patients' clinical evolution.
After each treatment, the Immunosorba® columns are preserved and regenerated for the next treatment, since each par of columns are re-usable for the same patient.
